You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Durvalumab

Showing 676 - 691 of 691
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Tumor Malignant, Interstitial Lung Disease Trial in Warszawa (Prolonged glucocorticosteroid (prednisone) regimen, Short

Unknown status
  • Lung Neoplasm Malignant
  • Interstitial Lung Disease
  • Prolonged glucocorticosteroid (prednisone) regimen
  • Short glucocorticosteroid (prednisone) regimen
  • Warszawa, Mazowieckie, Poland
    Instutut Gruzlicy I Chorob Pluc
Feb 26, 2020

LYMPHOMA Trial in Singapore (Durvalumab, Lenali)

Unknown status
  • LYMPHOMA
  • Singapore, Singapore
  • +3 more
Feb 15, 2017

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Worldwide (MEDI4736 monotherapy, tremelimumab+MEDI4736)

Completed
Has Results
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Tampa, Florida
  • +20 more
Jul 9, 2018

Part A and B: Advanced Solid Malignancies, Part C: Malignant Mesothelioma Trial in Japan (Tremelimumab, MEDI4736)

Completed
  • Part A and B: Advanced Solid Malignancies
  • Part C: Malignant Mesothelioma
  • Bunkyo-ku, Japan
  • +10 more
Dec 11, 2018

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck Trial in Worldwide (MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab)

Completed
Has Results
  • Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
  • Birmingham, Alabama
  • +124 more
Sep 11, 2020

Carcinoma, Non-Small Cell Lung Trial in Jinan (Consolidation Sintilimab)

Unknown status
  • Carcinoma, Non-Small Cell Lung
  • Consolidation Sintilimab
  • Jinan, Shandong, China
    Shandong Cancer Hospital
Mar 19, 2019

Squamous Cell Carcinoma of the Head and Neck Trial in Canada, United States (MEDI4736, tremelimumab)

Completed
  • Squamous Cell Carcinoma of the Head and Neck
  • MEDI4736
  • tremelimumab
  • Scottsdale, Arizona
  • +22 more
Oct 20, 2017

Lung Adenocarcinoma Trial in Guangzhou (Bevacizumab, chest radiation, concurrent chemo)

Unknown status
  • Lung Adenocarcinoma
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Apr 3, 2019

Advanced Solid Tumors, Aggressive B-cell Lymphomas Trial in United States (MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab,

Terminated
Has Results
  • Advanced Solid Tumors
  • Aggressive B-cell Lymphomas
  • MEDI6469 Monotherapy
  • +3 more
  • Scottsdale, Arizona
  • +12 more
Jun 1, 2017

Extensive-stage Small Cell Lung Cancer, Radiotherapy, Immunotherapy Trial in Beijing (PD-1 inhibitor JS-001)

Unknown status
  • Extensive-stage Small Cell Lung Cancer
  • +2 more
  • PD-1 inhibitor JS-001
  • Beijing, Beijing, China
    Cancer Insititute and Hosiptal of Chinese Academy of Medical Sci
Jun 2, 2019

DLBCL, Follicular Lymphoma Trial in United States (Ibrutinib, MEDI4736)

Completed
Has Results
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Birmingham, Alabama
  • +10 more
Jun 3, 2019

NSCLC Trial (durvalumab, bavituximab)

Withdrawn
  • Non-Small Cell Lung Cancer
  • durvalumab
  • bavituximab
  • (no location specified)
Jul 28, 2016

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United Kingdom, United States (MEDI4736 in combination with nab-paclitaxel

Completed
Has Results
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • MEDI4736 in combination with nab-paclitaxel and gemcitabine
  • MEDI4736 in combination with AZD5069
  • Rochester, New York
  • +6 more
Jul 26, 2019

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (MEDI4736 + tremelimumab, MEDI4736, Tremelimumab)

Completed
Has Results
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • MEDI4736 + tremelimumab
  • +3 more
  • Los Angeles, California
  • +27 more
Jun 2, 2020

PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of

Completed
  • Squamous Cell Carcinoma of the Head and Neck
    • La Jolla, California
    • +17 more
    Nov 10, 2017

    Pleural Mesothelioma, Peritoneal Mesothelioma Trial in Siena (tremelimumab plus MEDI4736)

    Unknown status
    • Pleural Mesothelioma
    • Peritoneal Mesothelioma
    • tremelimumab plus MEDI4736
    • Siena, Italy
      Medical Oncology and Immunotherapy Division, University Hospital
    Oct 26, 2015